TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
5.62
+0.12 (2.18%)
Mar 28, 2025, 4:00 PM EDT - Market closed
TriSalus Life Sciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for TriSalus Life Sciences stock have an average target of 11.75, with a low estimate of 10 and a high estimate of 16. The average target predicts an increase of 109.07% from the current stock price of 5.62.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TriSalus Life Sciences stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +95.73% | Mar 28, 2025 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +95.73% | Jan 24, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $10 | Buy | Initiates | $10 | +77.94% | Dec 17, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +95.73% | Nov 15, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +95.73% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
45.74M
from 29.43M
Increased by 55.43%
Revenue Next Year
68.66M
from 45.74M
Increased by 50.09%
EPS This Year
-0.56
from -1.32
EPS Next Year
-0.30
from -0.56
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 50.7M | 88.8M | 111.9M | ||
| Avg | 45.7M | 68.7M | 96.0M | ||
| Low | 42.1M | 59.0M | 73.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 72.3% | 94.1% | 63.0% | ||
| Avg | 55.4% | 50.1% | 39.9% | ||
| Low | 43.2% | 29.0% | 7.2% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -0.20 | 0.70 |
| Avg | -0.56 | -0.30 |
| Low | -0.98 | -0.80 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.